No Eudamed, No Problem! Latest Guidance Explains Alternatives While Database Is Built

Lack of an official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.

Traffic lights

Clarification about how the various actors, manufacturers, notified bodies and competent authorities should exchange information in the context of the Medical Device Regulation, pending the official launch of the new version of the Eudamed database, is now available. The Medical Device Coordination Group (MDCG) has endorsed a 31-page guidance on harmonized administrative practices and alternative technical solutions (MDCG 2021-1).

Eudamed Timeframe

Eudamed provides the framework to enable the much-demanded transparency in the new regulatory system. It cannot fully apply until all six inter-related modules are ready.

It was originally foreseen that it would be up and running May 2020. But now, it is not due to be officially launched until 26 May 2022, the date of the full application of the IVD Regulation, and exactly one year after the delayed MDR fully applies.

Even after launch, there is a transition period allowing actors in the sector another six months after publication of the notice in the Official Journal of the EU declaring the database fully functional until they need to fully comply. (Requirements set out in MDR Articles 29(4) relating to the registration of devices, and Article 56(5) relating to notified body certificates will fully apply 24 months after the notice.)

In the meantime, and to assist companies in already becoming compliant as far as possible with the new database, parts of Eudamed are being launched on a voluntary basis. Until Eudamed is fully functional and the official notice has been published the use of these parts Eudamed remains voluntary.

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Europe

Global Medtech Guidance Tracker: September 2024

 
• By 

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.

TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

 

TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.

J&J MedTech Keeps Up Cardiovascular Momentum With Shockwave E8 Launch In US

Tim Schmid, executive VP and worldwide chairman of J&J MedTech, expects Shockwave, acquired in April, and Abiomed, purchased in late 2022, to be “long-term gems” for the company. Cardiovascular is among higher-growth segments where J&J has concentrated investments in recent years, along with robotic surgical systems.

Pilot To Program: FDA Issues Accreditation Scheme For Conformity Assessment Draft Guidances

 

The US FDA has published a trio of draft guidance documents for its Assessment Scheme for Conformity Program, which began as a pilot in September 2020 to capitalize on the role of standards in the regulation of medical devices.

More from Geography

Pilot To Program: FDA Issues Accreditation Scheme For Conformity Assessment Draft Guidances

 

The US FDA has published a trio of draft guidance documents for its Assessment Scheme for Conformity Program, which began as a pilot in September 2020 to capitalize on the role of standards in the regulation of medical devices.

Biocomposites Fully Acquires SYNICEM And Subiton Lines, Launches NanoBone In UK

 

UK-based Biocomposites will begin selling in the UK its next-generation osteoinductive bone graft substitute, NanoBone, which came with its acquisition of Artoss GmbH in June 2023. Meanwhile, the company has purchased remaining shares in the manufacturers of SYNICEM and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers.

Senseonics Readies For US Launch Of 'World’s First One-Year CGM'

 

US FDA has greenlighted Senseonics’ Eversense 365 continuous glucose monitor, which must be replaced just once a year. Capable of being integrated with compatible insulin pumps as part of an automated insulin delivery system, the fully implantable device lasts 185 days longer than the Eversense E3 sensor and far outstrips competing CGMs, which last only for 10-14 days.